Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Tax Provisions (2016 - 2025)

Historic Tax Provisions for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $99.3 million.

  • United Therapeutics' Tax Provisions rose 2490.57% to $99.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $394.7 million, marking a year-over-year increase of 2070.34%. This contributed to the annual value of $343.9 million for FY2024, which is 1879.1% up from last year.
  • United Therapeutics' Tax Provisions amounted to $99.3 million in Q3 2025, which was up 2490.57% from $98.9 million recorded in Q2 2025.
  • In the past 5 years, United Therapeutics' Tax Provisions registered a high of $101.3 million during Q1 2025, and its lowest value of $4.2 million during Q1 2021.
  • Over the past 5 years, United Therapeutics' median Tax Provisions value was $76.0 million (recorded in 2023), while the average stood at $67.1 million.
  • In the last 5 years, United Therapeutics' Tax Provisions tumbled by 8761.06% in 2021 and then surged by 153809.52% in 2022.
  • Over the past 5 years, United Therapeutics' Tax Provisions (Quarter) stood at $28.3 million in 2021, then soared by 65.02% to $46.7 million in 2022, then skyrocketed by 67.67% to $78.3 million in 2023, then grew by 21.58% to $95.2 million in 2024, then rose by 4.31% to $99.3 million in 2025.
  • Its Tax Provisions stands at $99.3 million for Q3 2025, versus $98.9 million for Q2 2025 and $101.3 million for Q1 2025.